Stock Groups

U.S. FDA authorizes AstraZeneca’s COVID-19 antibody drug -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILEPHOTO: AstraZeneca’s logo can be seen outside of its North America headquarters at Wilmington, Delaware (U.S.A), March 22nd 2021. REUTERS/Rachel Wisniewski

(Reuters] – AstraZeneca (NASDAQ) announced Wednesday that it has approved AstraZeneca’s antigen cocktail for COVID-19 prevention in those with weak immune systems, or who have suffered from severe side effects of coronavirus vaccines.

Many vaccines depend on the immune system’s ability to produce targeted antibodies and fight infection. However, AstraZeneca’s Evusheld therapy contains laboratory-made antibodies that can linger for several months in the body to stop the virus from spreading.

“Vaccines have been shown to be the best defense against COVID-19,” said Patrizia Cazzoni, Director of the Center for Drug Evaluation and Research.

The FDA stated that Evusheld does not replace COVID-19 vaccine in pre-exposure prevention.

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]